Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 429 Shares of Stock

Nektar Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Howard Robin sold 429 shares at an average $35.85, a transaction worth about $15,380. The sale covered tax withholding on vested equity awards; he retained 54,198 shares.
  • Nektar shares fell 5.5% to $32.54, near their 12-month low. Quarterly EPS loss of $1.63 was narrower than expected, while revenue of $9.39 million missed estimates.
  • HC Wainwright reiterated its Buy rating and $185 target after improving longer-term earnings forecasts, but still expects losses through 2029. Analysts’ consensus rating is Moderate Buy.
  • MarketBeat previews top five stocks to own in December.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard Robin sold 429 shares of the firm's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $35.85, for a total transaction of $15,379.65. Following the completion of the sale, the chief executive officer owned 54,198 shares in the company, valued at approximately $1,942,998.30. The trade was a 0.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nektar Therapeutics Trading Down 5.5%

NASDAQ:NKTR traded down $1.88 during trading hours on Thursday, hitting $32.54. 872,282 shares of the company traded hands, compared to its average volume of 1,058,000. Nektar Therapeutics has a twelve month low of $32.51 and a twelve month high of $109.00. The firm has a 50-day moving average of $46.15 and a 200 day moving average of $64.53. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.04 and a beta of 1.44.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 29.31%. The company had revenue of $9.39 million for the quarter, compared to the consensus estimate of $10.27 million. Equities research analysts predict that Nektar Therapeutics will post -7.39 earnings per share for the current fiscal year.

Key Stories Impacting Nektar Therapeutics

These are some of the NKTR stories that stood out recently:

  • Positive Sentiment: HC Wainwright improved its 2026 and 2027 EPS forecasts, including raising its FY2026 estimate to a loss of $7.06 per share from $7.49 and its FY2027 estimate to a loss of $8.40 from $8.83. It also trimmed projected losses for each quarter from Q4 2026 through Q4 2027. MarketBeat analyst estimate update
  • Positive Sentiment: The analyst raised its FY2028 and FY2029 EPS forecasts to losses of $9.23 and $6.08 per share, respectively, and increased its FY2030 estimate to a profit of $0.59 from $0.35. HC Wainwright reiterated its Buy rating and $185 target. MarketBeat analyst estimate update
  • Neutral Sentiment: Despite the revisions, HC Wainwright still forecasts losses through FY2029, so the estimate improvements do not indicate near-term profitability.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Two Seas Capital LP raised its holdings in shares of Nektar Therapeutics by 8.2% in the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company's stock worth $202,582,000 after buying an additional 253,744 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Nektar Therapeutics by 171.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 621,249 shares of the biopharmaceutical company's stock valued at $37,614,000 after buying an additional 392,759 shares in the last quarter. Braidwell LP boosted its stake in Nektar Therapeutics by 112.7% in the 2nd quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company's stock valued at $33,063,000 after buying an additional 250,916 shares in the last quarter. Orbimed Advisors LLC bought a new stake in Nektar Therapeutics in the first quarter valued at $19,786,000. Finally, ADAR1 Capital Management LLC grew its position in Nektar Therapeutics by 123.9% in the first quarter. ADAR1 Capital Management LLC now owns 161,252 shares of the biopharmaceutical company's stock valued at $11,602,000 after acquiring an additional 89,221 shares during the period. 75.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on NKTR shares. JPMorgan Chase & Co. initiated coverage on Nektar Therapeutics in a research report on Friday, August 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Canaccord Genuity Group lowered their price objective on Nektar Therapeutics from $153.00 to $149.00 and set a "buy" rating on the stock in a research report on Monday. TD Cowen upgraded Nektar Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. BTIG Research reaffirmed a "buy" rating and issued a $178.00 target price on shares of Nektar Therapeutics in a research report on Friday, October 9th. Finally, Wall Street Zen downgraded shares of Nektar Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 14th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $130.33.

View Our Latest Stock Report on Nektar Therapeutics

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.

Read More

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nektar Therapeutics Right Now?

Before you consider Nektar Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.

While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines